Towards improving diagnosis of memory loss in general practice:TIMeLi diagnostic test accuracy study protocol by Creavin, Sam T. et al.
                          Creavin, S. T., Cullum, S. J., Haworth, J., Wye, L., Bayer, A., Fish, M., ...
Ben-Shlomo, Y. (2016). Towards improving diagnosis of memory loss in
general practice: TIMeLi diagnostic test accuracy study protocol. BMC
Family Practice, 17(1), [79]. DOI: 10.1186/s12875-016-0475-2
Publisher's PDF, also known as Version of record
License (if available):
CC BY
Link to published version (if available):
10.1186/s12875-016-0475-2
Link to publication record in Explore Bristol Research
PDF-document
This is the final published version of the article (version of record). It first appeared online via BioMed Central at
http://bmcfampract.biomedcentral.com/articles/10.1186/s12875-016-0475-2. Please refer to any applicable
terms of use of the publisher.
University of Bristol - Explore Bristol Research
General rights
This document is made available in accordance with publisher policies. Please cite only the published
version using the reference above. Full terms of use are available:
http://www.bristol.ac.uk/pure/about/ebr-terms.html
STUDY PROTOCOL Open Access
Towards improving diagnosis of memory
loss in general practice: TIMeLi diagnostic
test accuracy study protocol
Sam T. Creavin1*, Sarah J. Cullum1, Judy Haworth2, Lesley Wye1, Antony Bayer3, Mark Fish4, Sarah Purdy1
and Yoav Ben-Shlomo1
Abstract
Background: People with cognitive problems, and their families, report distress and uncertainty whilst undergoing
evaluation for dementia and perceive that traditional diagnostic evaluation in secondary care is insufficiently patient
centred. The James Lind Alliance has prioritised research to investigate the role of primary care in supporting a
more effective diagnostic pathway, and the topic is also of interest to health commissioners. However, there are
very few studies that investigate the accuracy of diagnostic tests for dementia in primary care.
Methods: We will conduct a prospective diagnostic test accuracy study to evaluate the accuracy of a range of simple
tests for diagnosing all-cause-dementia in symptomatic people aged over 70 years who have consulted with their
general practitioner (GP). We will invite eligible people to attend a research clinic where they will undergo a range of
index tests that a GP could perform in the surgery and also be assessed by a specialist in memory disorders at the
same appointment. Participating GPs will request neuroimaging and blood tests and otherwise manage patients in line
with their usual clinical practice. The reference standard will be the consensus judgement of three experts (neurologist,
psychiatrist and geriatrician) based on information from the specialist assessment, GP records and investigations, but
not including items in the index test battery. The target condition will be all-cause dementia but we will also
investigate diagnostic accuracy for sub-types where possible. We will use qualitative interviews with patients
and focus groups with clinicians to help us understand the acceptability and feasibility of diagnosing dementia in
primary care using the tests that we are investigating.
Discussion: Our results will help clinicians decide on which tests to perform in someone where there is concern about
possible dementia and inform commissioning of diagnostic pathways.
Keywords: Dementia, Primary care, General practice, Sensitivity and specificity, Diagnostic tests
Background
Dementia is a syndrome of global cognitive impairment
which represents a decline from a previous level of func-
tioning, often with behavioural and psychiatric symp-
toms [1], that affects around 750,000 people in the UK,
of whom half have a diagnosis recorded on GP records
[2]. Dementia, recently termed “major neurocognitive
disorder” [3, 4], is categorised according to clinical fea-
tures and presumed aetiology with the common clinical
diagnoses being Alzheimer’s [5, 6], ischaemic cerebro-
vascular disease [7], Lewy body disease [8, 9], tauopathy/
frontotemporal dementia [10], and other rarer causes.
All-cause-dementia is also defined, without additional
specified clinical features needed for the subtype defini-
tions [11–13].
In the population, Alzheimer’s disease and vascular
pathology are the major neuropathological features
that are associated with dementia syndrome [14], but
there are often multiple contributing elements [14, 15].
The association between Alzheimer’s disease path-
ology and dementia is strongest in the young-old and
weakens with age [16], leading some investigators to
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question the value of presumed aetiological diagnosis
in a population where mixed pathology is usual [17, 18].
Mild cognitive impairment (MCI) [19] is a syn-
drome of cognitive impairment that is greater than
expected when accounting for age and educational
attainment but that does not affect activities of daily
life. MCI affects between 0.1 and 42 % of adults de-
pending on which definition is used [20], and the
prognosis in general practice is variable: approxi-
mately 25 % of people develop dementia within three
years but around 40 % revert to normal [21]. Experi-
ence in clinical general practice is that when there
are concerns about impaired cognition these are fo-
cussed primarily on the possibility of dementia ra-
ther than MCI, but inevitably some people who are
evaluated for possible dementia will be diagnosed
with MCI. In this protocol we include people who
are ultimately diagnosed as having MCI when we
refer to a person consulting with a GP about pos-
sible dementia (e.g. under “participants”), because it
would be unusual for a person to consult a GP
about possible MCI.
People with cognitive problems and their families
experience uncertainty while undergoing evaluation
for possible dementia [22] and the role of primary
care in supporting a more effective route to diagnosis
has been identified as a priority for health research
[23]. Health policy changed significantly between
2010-2015: in the USA Medicare has included an an-
nual cognitive check-up since 2013 [24]; in England
case-finding for dementia started in 2014 [25] and
more recently GPs have been encouraged to take a
more active role in diagnosing dementia independent
of a specialist opinion [26].
Despite this change in health policy, few research stud-
ies exist to provide an evidence-based approach to the
diagnosis of dementia in general practice and by GPs
[27–33]. Often tests have been evaluated as tools for
screening rather than diagnosis [34] and commonly used
tests, such as the Montreal Cognitive Assessment (MOCA
[35]) and Informant Questionnaire for Cognitive disorders
in the Elderly (IQCODE [36]) have not been well evalu-
ated in primary care [37, 38]. GPs are uncertain about
diagnosing dementia and report working collaboratively
with the memory nurse over up to four consultations
before reaching a diagnosis [39].
We previously found that the diagnostic accuracy of
simple questions concerning functioning and independ-
ent living was comparable to longer more established
measures of cognitive functioning in a group of men
who had been screened for cognitive problems [40].
Here we describe a prospective study to evaluate the ac-
curacy of a range of tests for diagnosing dementia in a
primary care setting.
Methods
Summary
We will conduct a prospective diagnostic test cohort
study to evaluate the accuracy of a range of index tests
(detailed below) for diagnosing dementia in symptomatic
adults over the age of 70 years. The primary target con-
dition is all-cause dementia; we will also examine the
diagnostic accuracy for probable Alzheimer’s disease as
compared to other causes of dementia. This study has
been peer reviewed by the funding bodies. The back-
ground, aims and broad methods were reviewed as part
of a competitive fellowship award. The funders were
fully aware that over the course of the fellowship a more
detailed protocol would be produced and there may be
minor changes to the design in light of further work.
These amendments are not re-reviewed by the funder.
Participants
Setting
We will conduct the study in GP practices in the Bristol,
North Somerset and South Gloucestershire region, in
the South West of England with a total population of
972,417 people, with 16 % aged over 65 years and 11 %
aged over 70 years. All 54 practices in the NIHR West-
ern Clinical Research Network (CRN) of GP practices
contributing to NHS (National Health Service) research
infrastructure ([41]) will be invited to take part and refer
patients to the study team. Research clinics will be held
in practices within the CRN selected on the basis of
geographic accessibility for local participants.
Recruitment
We will include people aged 70 years and over (i.e. who
have had their 70th birthday) where concerns have been
raised in the community about the possibility of demen-
tia by the patient or others (including GP), but in whom
the diagnosis has yet to be confirmed. The symptoms
must have been present for at least six months and been
gradual in onset and progression. We will exclude
people with clinical “red-flags”: co-incident tremor,
weakness or dysphasia; existing diseases listed in Table 1;
mental health problems needing secondary care input;
Table 1 Conditions resulting in exclusion from TIMeLi study
Prior diagnosis of a parkinsonian condition (including
Parkinson’s disease)
Multiple sclerosis
Learning disability
Motor neuron disease
Huntington’s disease
Registered blind
Severe hearing impairment (operationalised as unable to
use telephone)
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terminal illness; or inability to attend research clinic with
an informant. People with these conditions will almost
always need specialist input to make a diagnosis of de-
mentia, and an informant history is required for a robust
diagnosis of dementia. Additionally we will exclude
people with severe dementia (operationalised as lack of
capacity to consent) as diagnosis in this group is less
challenging.
Figure 1 outlines the process of the study. GPs will
pass details on potential participants, after participant
consent, to the research study by completing a template
form that is then emailed to a secure nhs.net email ad-
dress [42]. At the time of referral, the GPs are asked to
state their prior belief (“gut feeling”) concerning the
diagnosis and their confidence in this diagnosis (see “test
methods | index tests” below for more detail). No prior
testing is required to determine eligibility for the study,
the only requirements are listed in the inclusion and ex-
clusion criteria above. Investigations such as blood tests
and neuroimaging will be requested by the GP in line
with their usual clinical practice and can be conducted
in parallel with attendance at the study clinic as the re-
sults will not be available to the researcher at the clinic.
An administrator will process forms from the GP so that
the researcher’s clinical evaluation of participants is
blinded to the GP judgement, and this will only be made
available to the study team at the analysis stage.
Sampling
The eligible study population will be defined by a con-
secutive series of patients who meet the criteria for
recruitment, but we recognise that not everybody who is
eligible will participate. Table 2 shows some of the rea-
sons for non-participation of eligible patients and how
we will try to minimise bias.
A particular problem is that GPs might not mention
the study to people who are eligible because they forget
to do so. To address this we will use an electronic
prompt within the electronic medical record. Figure 2
outlines the computer prompts that are triggered when
the GP enters a problem heading related to memory
problems or cognitive difficulties during the consultation
with the patient.
The computer prompts will help us to monitor prac-
tices for potentially eligible patients who have not partic-
ipated using electronic searches of coded data in the
electronic medical record.
Data collection
Research clinics will be held in GP practices in the
NIHR Western CRN. At the research clinic one GP re-
search doctor (STC) will see one patient-informant dyad
for the index tests and simultaneously a dementia spe-
cialist doctor (JH) will see a different participant dyad
for the specialist assessment of up to one hour in a sep-
arate room. Participants will have a 10-min rest before
crossing over to see the other doctor and will be at the
clinic for approximately 2.5 h in total. We aim that
half of participants will see each doctor first, but the
order of consultations will be determined by patient
availability for appointments. So that the index tests
and specialist assessment are conducted independently
Fig. 1 TIMeLi study process
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of investigations, test results will be electronically ex-
tracted by the study team at the end of the study,
and will not be available on the day of the research
clinic, though they will be available to inform the ref-
erence standard. We planned data collection and ana-
lysis in advance.
Test methods
Index tests
GPs often use heuristics when making diagnoses [43–45],
including the possibility of dementia [46, 47]. Referring
GPs will be asked to give their “gut feeling” about the pos-
sibility of dementia, based on their brief interaction with
the patient during the consultation at the time of referral.
We will ask GPs to report whether they think the person
has dementia, cognitive impairment (but not dementia),
or is cognitively normal. In addition they are asked to rate
their diagnostic confidence using a 10 cm visual analogue
scale which is then converted to a percentage (prior prob-
ability) and their rationale for their opinion.
In deciding what simple index tests should be evalu-
ated, we reviewed the literature to identify cognitive tests
and also referred to a guide to clinicians about tests that
could be used in primary care [48]. We selected tests for
the index battery on the basis of the following criteria:
1. Available to use for free – i.e. not copyright
(therefore MMSE [49] excluded);
2. Previously evaluated in a primary care setting in at
least one study;
3. Not been evaluated in primary care before but
conceptually of interest (Timed up and go; Sniffin’
sticks).
Based on these criteria we selected studies with good
diagnostic accuracy (Youden index [50] of greater than
0.75 or a sensitivity or specificity of greater than 0.85 at
the optimal reported threshold) and judged the studies
diagnostic accuracy against the time taken to conduct
the test, favouring brief tests with high specificity. On
this basis the following tests (“index battery”) were se-
lected to be included in the index battery: Memory alter-
ation test (M@T, [51]), Eurotest [27], Phototest [52],
Scenery picture memory test [53], 6CIT [54], GPCOG
[55], Mini-Cog [56], Time and change [57], Timed up-
and-go [58], Extra pyramidal signs scale [59], Sniffin’
sticks [60, 61]. We also included assessments of activities
of daily living; the Pfeffer [62], Lawton [63] Katz [64],
AD8 [65] and Informant questionnaire for cognitive
disorders in the elderly (IQCODE) short version [36]. A
different group of investigators have reviewed the use of
cognitive tests in primary care [66], compared to the
tests identified by that group our battery does not in-
clude memory impairment screen (MIS) [67] or abbrevi-
ated mental test (AMT) [68] but does include indicators
which reflect similar aspects of cognitive testing and are
possibly more culturally fair, and which have fewer
restrictions on use. In the MIS (all rights reserved), pa-
tients are asked to read from a list of four words, then
engaged in a distractor activity and finally scored on free
Table 2 Possible reasons for non-participation of eligible
patients
Potential barrier to recruitment How we will address this
GP factors
Not thinking of the study
when it is relevant
Computer prompts when relevant
problem code entered
Being too busy to discuss
it with patients
Computer prompt to record this
Believing that a patient is
not suitable
Computer prompt to record this
Patient factors
Difficulty accessing research
clinic [day, time, travel]
Provide transport if needed, range of
clinics on different days and times
Other health issues Allow people to rearrange appointment
if needed
Wanting time to decide Allow people time to think and call
back
No clear reason but declined Computer prompt to record study
declined
Fig. 2 Computer prompts to aid participation
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and cued recall; in comparison Phototest (which is avail-
able for use under a creative commons license [69])
requires participants to identify six photos, perform a dis-
tractor task and then tests free and cued recall. We include
six of the 10 items in the AMT in our index battery and
exclude age and recognition of two people (which are ar-
guably less discriminative in people without severe impair-
ment) year of First World War and name of present
monarch (which are arguably more culturally determined).
We did not initially include the Montreal Cognitive As-
sessment (MoCA, [35]) in the index battery as it was ori-
ginally designed to diagnose or identify MCI, had been
advocated for use in secondary care [48] and had not been
investigated in primary care [38]. However, we revised our
protocol in light of subsequent policy changes in 2015 that
encouraged GPs to diagnose dementia in typical situations
without referring to a specialist [26] using the MoCA as
the preferred instrument. We replaced the M@T with the
MoCA because we judged that including both the MoCA
and the M@T would be overly burdensome for partici-
pants and have little added value.
Index tests will be performed as instructed by the ori-
ginal authors by a single doctor who has completed
postgraduate training in general practice (STC), who will
not be aware of any other clinical information about the
participants, including the GPs “gut feeling” about the
possibly of dementia. The full index battery takes around
25 min in a healthy person and around 50 min in a
person with dementia.
Specialist assessment
A single dementia specialist (JH) will perform a standar-
dised clinical evaluation lasting approximately an hour,
comprising clinical history, the Addenbrooke’s Cognitive
Examination third edition (ACE-III) [70], Brief Assess-
ment Schedule Depression Cards (BASDEC) [71] and
the Bristol activities of daily living questionnaire (BADL)
[72]. The specialist will not have access to any investiga-
tion results because we want to assess the accuracy of
clinical assessment by a specialist. If the specialist con-
siders that further investigations and assessment are
needed to exclude a rare dementia aetiology we will sug-
gest to the referring GP that they may wish to refer the
patient to the National Health Service (NHS) memory
clinic. The specialist will be asked to reach a clinical
judgement about the cognitive status of participants
operationalised as normal, cognitive impairment, or
dementia, as well as the most likely aetiology of the
dementia based on the information available to them.
Reference standard
The reference standard will be the consensus judgement
by an expert panel about the diagnosis of dementia,
using information from the specialist assessment, blood
tests, neuroimaging, and medical records (where
needed). Information from the index battery and GP
“gut feeling” will not contribute to the reference stand-
ard. We will allow the reference panel access to the re-
sults of any tests that have been conducted up to six
months after a research clinic because in some cases
special tests such as regional cerebral blood flow single
photon emission computed tomography (SPECT) or
dopamine transporter imaging (DAT) scans may have
been requested and would help refine the reference
standard. We will use a stepwise-reveal process for all
items that contribute to the reference panel, starting
with the anonymised demographics, medical history and
clinical assessment from the research clinic, followed by
blood tests and routine neuroimaging such as plain
computed tomogram (CT) or plain magnetic resonance
imaging (MRI), followed by additional information from
medical records and additional tests such as DAT or
SPECT scans or neuropsychology results (if available).
We intend to use a staged decision making approach for
assigning the final diagnosis [73] where each expert
initially assigns a diagnosis independently and then
discordant cases are discussed.
Definitions
To account for differences between definitions [74] we
will apply three different criteria for dementia: Diagnos-
tic and Statistical Manual of Mental Disorders (DSM) IV
[12], DSM 5 [3] and the International Classification of
Diseases Tenth edition (ICD 10 [11]). For cognitive im-
pairment that does not meet criteria for dementia we
will use two definitions: DSM 5 [3] mild neurocognitive
disorder and Peterson MCI [19]. The final reference
standard for the main analysis will be the consensus
judgement about the presence or absence of dementia,
cognitive impairment or normal cognition, based on the
application of the three definitions above. An example of
how we might assign diagnoses is in Table 3.
We will also investigate how the prevalence of MCI
and dementia, and the accuracy of tests for diagnosis,
varies with the three different definitions. We will then
define subtypes of dementia according to standard defi-
nitions: Alzheimer’s disease [6], vascular [7], frontotem-
poral [10] and Lewy body [9].
Follow-up
We will follow consenting participants electronically
using their GP records for up to seven years to deter-
mine whether those who do not have dementia at base-
line develop it later on, and whether participants who
are identified as having dementia by the study specialist
assessment subsequently have their diagnosis refined.
We will use follow-up data to analyse the diagnostic
accuracy of tests for the diagnosis of dementia in the
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future (“delayed verification”) but the reference standard
for the cross-sectional diagnosis of dementia will not
take account of information that occurred more than six
months subsequent to the research clinic.
Statistical methods
Sample size
Table 4 shows the sample size required for a given
lower 95 % confidence interval (LCI) based on a spe-
cificity of 95 % and a prevalence of dementia of 75 %.
We used standard tables for the sample size calcula-
tion [75].
Other investigators have reported a specificity of be-
tween 89 % [29] and 94 % [76] for unaided “gut feeling” of
GPs for diagnosing dementia, and individual tests such as
clock draw (specificity 96 % [33]), Timed up-and-go (spe-
cificity 89 % [33]) and Phototest (specificity 89 % [52]) also
have high specificity. We aim to recruit a sample of be-
tween 200-300 people. Using the five events per variable
rule [77] this would allow us to evaluate between 30 and
45 diagnostic indicators (at 75 % prevalence of dementia).
Analysis
The plan for analysis may change with methodological
advances in diagnostic science, but the current plan is
outlined. We will construct 2x2 tables for each diagnos-
tic indicator in the index battery and the outcome de-
mentia, as defined by the consensus panel. We will also
evaluate the discriminative ability of diagnostic indica-
tors by calculating the area under the curve.
Table 3 Example of process for assigning the reference standard
Assessor AB MF SJC
Role Consultant geriatrician with interest in
memory disorders
Consultant neurologist Consultant old age
psychiatrist
Study ID XX1 XX1 XX1
Status: Dementia/major neurocognitive disorder DSM 5 or MCI [19]/mild neurocognitive disorder DSM 5 or Normal
DSMa IV [12] Dementia Dementia Dementia
DSMa 5 [13] Major neurocognitive disorder Mild neurocognitive
disorder
Major neurocognitive
disorder
ICD 10b [11] MCI Dementia Dementia
Overall Dementia Dementia Dementia
Consensus judgement Dementia
Aetiological subtype
Alzheimer’s disease probable [6] X X
Alzheimer’s disease possible [6] X
Ischaemic cerebrovascular disease dementia
probable [7]
Ischaemic cerebrovascular disease dementia
possible [7]
Mixed aetiology [13]
Parkinson’s [13]
Lewy Body Dementia probable [8, 9, 13]
Lewy Body Dementia possible [8, 9, 13]
Tauopathy/Frontotemporal dementia [10]
Other (describe) [13]
Uncertain [13]
Consensus judgement Alzheimer’s disease probable [6]
Notes: For the main analysis participant XX1 would be classed as having dementia
aDiagnostic and statistical manual of mental disorders/
bInternational classification of diseases
Table 4 Sample size for diagnostic test accuracy study,
assuming specificity of 95 % and prevalence of dementia of
75 %
Lower 95 %
confidence
interval of
specificity
Number of healthy
people needed for
lower confidence
interval
Number of people
with dementia needed
for lower confidence
interval
Total
sample
size
85 % 93 279 372
80 % 50 150 200
75 % 34 102 136
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We will use logistic regression models with the target
condition (dementia) as defined by the consensus panel
being the binary dependent variable, and the diagnostic
indicators as the independent variable. We will only in-
clude diagnostic indicators that have a p value of less
than 0.10 in univariable logistic regression in the multi-
variable analysis. When we perform multivariable ana-
lysis we will include diagnostic indicators in the order in
which they would be performed in clinical practice, for
example age and sex (if significant), followed by GP “gut
feeling” (if significant) followed by any tests in the index
battery (ordered by mean average time taken to perform
test). This will allow us to calculate the diagnostic accur-
acy of (e.g.) “gut feeling” allowing for the contribution of
age and sex. We will calculate standard measures of
diagnostic accuracy (sensitivity, specificity, likelihood ra-
tios, area under the curve and predictive values) together
with 95 % confidence intervals. We will use the regres-
sion coefficients to calculate predicted risks of dementia
in participants and compare these to the actual risk
using goodness of fit tests [78]. We will also consider
analysing decision curves and evaluating the net reclassi-
fication index and integrated discrimination index [79].
Missing values will be imputed using multiple imput-
ation by chained equations [80, 81]. We will perform a
bootstrapping procedure to validate the final model and
shrink the regression parameters [82]. We will use the
model to construct a diagnostic algorithm and decision
rule for use in clinical practice.
Qualitative evaluation of acceptability and feasibility
We will use joint interviews with a subsample of ap-
proximately 30 patients and their carers who attended a
research clinic to determine how acceptability they
would find a GP based diagnosis of dementia. The inter-
view will be conducted after the research clinic. Partici-
pants will be purposefully sampled on the characteristics
of age and GP practice (as a measure of deprivation and
experience of general practice). We will not select people
based on their diagnosis as this will not be known to the
researcher at the research clinic. We will not offer par-
ticipation when the researchers considers this would be
burdensome for participants and their informants, and
that this means that people with more severe cognitive
impairment are unlikely to participate. Interviews will
continue until saturation is reached. The topic guide will
explore participants’ experience of seeing their GP about
possible dementia, and then ask questions about the ac-
ceptability and perceived benefits and disadvantages of a
GP based diagnosis of dementia. We will use focus
groups with clinicians and managers in approximately
five local general practices to identify the feasibility and
barriers to a diagnostic evaluation for dementia taking
place in general practice.
Discussion
The TIMeLi study will be the first study, to our know-
ledge, to prospectively evaluate the diagnostic accuracy
of a range of indicators in symptomatic people in pri-
mary care. The particular strengths of the study are the
range of index tests that will be evaluated and the ability
to account for the “gut feeling” of GPs. In addition, the
study is being conducted in primary care with testing
being delivered by a GP.
We anticipate our results will help address uncertainty
about what tests are most useful to a GP to evaluate
someone for possible dementia. If we identify a set of
tests or diagnostic algorithm with high accuracy for
diagnosing dementia then individual GPs could apply
this in their clinical practice. Subsequent further work to
evaluate this could lead to some people with established
dementia being evaluated and diagnosed entirely in pri-
mary care, without specialist input. This does not pre-
clude the use of neuroimaging, to help determine the
likely aetiology of the dementia or to exclude alternative
diagnoses, or the role of specialists for younger patients,
more complex scenarios, or to provide aetiological diag-
nosis. Our results will inform the diagnostic approach to
patients with possible dementia in primary care.
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